[go: up one dir, main page]

NI201500163A - Composiciones, métodos y sistemas para el suministro por vía respiratoria de tres o más agentes activos. - Google Patents

Composiciones, métodos y sistemas para el suministro por vía respiratoria de tres o más agentes activos.

Info

Publication number
NI201500163A
NI201500163A NI201500163A NI201500163A NI201500163A NI 201500163 A NI201500163 A NI 201500163A NI 201500163 A NI201500163 A NI 201500163A NI 201500163 A NI201500163 A NI 201500163A NI 201500163 A NI201500163 A NI 201500163A
Authority
NI
Nicaragua
Prior art keywords
systems
active agents
methods
compositions
delivery via
Prior art date
Application number
NI201500163A
Other languages
English (en)
Inventor
Reisner Colin
Fitzgerald Darken Patrick
Lechuga-Ballesteros David
B Joshi Vidya
Kumar Dwivedi Sarvajna
Original Assignee
Pearl Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pearl Therapeutics Inc filed Critical Pearl Therapeutics Inc
Publication of NI201500163A publication Critical patent/NI201500163A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen composiciones farmacéuticas, sistemas y métodos adecuados para el suministro por vía respiratoria de una combinación fija de los agentes activos LAMA, LABA, e ICS. Las composiciones farmacéuticas descritas en el presente documento pueden formularse para el suministro por vía respiratoria a través de un inhalador de dosis medida (MDI). También se describen en el presente documento sistemas de MDI para la administración de una combinación fija de los agentes activos LAMA, LABA, e ICS, así como también se describen métodos para preparar y usar las composiciones y los sistemas descritos en el presente documento.
NI201500163A 2013-05-22 2015-11-20 Composiciones, métodos y sistemas para el suministro por vía respiratoria de tres o más agentes activos. NI201500163A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361826424P 2013-05-22 2013-05-22

Publications (1)

Publication Number Publication Date
NI201500163A true NI201500163A (es) 2016-01-06

Family

ID=50942948

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201500163A NI201500163A (es) 2013-05-22 2015-11-20 Composiciones, métodos y sistemas para el suministro por vía respiratoria de tres o más agentes activos.

Country Status (20)

Country Link
US (1) US20150150787A1 (es)
EP (1) EP2999460A1 (es)
JP (1) JP2016519160A (es)
KR (1) KR20160013134A (es)
CN (1) CN105392471A (es)
AU (1) AU2014268482A1 (es)
BR (1) BR112015028964A2 (es)
CA (1) CA2912927A1 (es)
CL (1) CL2015003422A1 (es)
CR (1) CR20150645A (es)
DO (1) DOP2015000284A (es)
HK (2) HK1221653A1 (es)
MX (1) MX2015016058A (es)
NI (1) NI201500163A (es)
PE (1) PE20160155A1 (es)
PH (1) PH12015502593A1 (es)
RU (1) RU2015154720A (es)
SG (1) SG11201509543YA (es)
WO (1) WO2014190204A1 (es)
ZA (1) ZA201509016B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010138884A2 (en) 2009-05-29 2010-12-02 Pearl Therapeutics, Inc. Compositions, methods & systems for respiratory delivery of two or more active agents
US8986710B2 (en) * 2012-03-09 2015-03-24 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
KR20160101928A (ko) * 2013-11-22 2016-08-26 테바 브랜디드 파마슈티컬 프로덕츠 알앤디, 인코포레이티드 흡입 약제
TWI602566B (zh) 2014-09-09 2017-10-21 維克杜拉有限公司 調配物、方法及裝置
TW201735914A (zh) * 2015-12-22 2017-10-16 阿斯特捷利康公司 用於治療慢性阻塞性肺疾病之醫藥組成物
US10098837B2 (en) 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD
ES2968212T3 (es) 2016-09-19 2024-05-08 Mexichem Fluor Sa De Cv Composición farmacéutica que comprende glicopirrolato
WO2019142214A1 (en) 2018-01-19 2019-07-25 Cipla Limited Pharmaceutical composition comprising tiotropium for inhalation
US20220000881A1 (en) * 2018-10-31 2022-01-06 Repurposed Therapeutics, Inc. Dba Defender Treatment of exposure to chlorine gas with scopolamine
CN112137957B (zh) * 2019-06-26 2022-07-29 长风药业股份有限公司 一种药用吸入气雾剂及其制备方法
CN111349036B (zh) * 2020-03-13 2022-03-08 安徽恒星制药有限公司 一种格隆溴铵的替代物及其制备方法和医药用途
CN111467498A (zh) * 2020-05-14 2020-07-31 王兆霖 药物组合物制剂
CN111617138A (zh) * 2020-07-07 2020-09-04 上海凯宝药业股份有限公司 痰热清在制备慢性阻塞性肺病急性加重治疗药物中的应用
FI4175619T3 (fi) 2021-07-09 2024-05-28 Astrazeneca Pharmaceuticals Lp Koostumuksia, menetelmiä ja järjestelmiä aerosolilääkkeen antamiseen
US20250057764A1 (en) * 2021-12-20 2025-02-20 Astrazeneca Ab Compositions, methods and systems for aerosol drug delivery

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
US3994974A (en) 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives
SE378109B (es) 1972-05-19 1975-08-18 Bofors Ab
CY1359A (en) 1981-02-02 1987-08-07 Schering Corp Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
US5707634A (en) 1988-10-05 1998-01-13 Pharmacia & Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
GB8903593D0 (en) 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
AU659645B2 (en) 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
GB9313642D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
SE9404080L (sv) 1993-12-28 1995-06-29 Ciba Geigy Ag Förfarande för framställning av en optiskt ren enantiomer av formoterol
US5837699A (en) 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
GB9413202D0 (en) 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
DE4440337A1 (de) 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US6258341B1 (en) 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
US6309671B1 (en) 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
ATE287703T1 (de) 1995-04-14 2005-02-15 Nektar Therapeutics Pulverförmige pharmazeutische formulierungen mit verbesserter dispergierbarkeit
US5833891A (en) 1996-10-09 1998-11-10 The University Of Kansas Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
US5886200A (en) 1996-07-01 1999-03-23 Schering Corporation Process for the preparation of 17-esters of 9 α, 21-dihalo-pregnane-11 β, 17 α-diol-20-ones
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
US6010935A (en) 1997-08-21 2000-01-04 Micron Technology, Inc. Self aligned contacts
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
PT102343B (pt) 1999-08-02 2003-11-28 Hovione Farmaciencia Sa Processo para a preparacao de furoato mometasona
TWI310688B (en) 1999-10-29 2009-06-11 Nektar Therapeutics Dry powder compositions having improved dispersivity
JP2007500234A (ja) 2003-05-28 2007-01-11 ネクター セラピューティクス 水に不溶な活性剤を含む医薬的成形
US8475845B2 (en) 2005-07-15 2013-07-02 Map Pharmaceuticals, Inc. Method of particle formation
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
WO2010138884A2 (en) * 2009-05-29 2010-12-02 Pearl Therapeutics, Inc. Compositions, methods & systems for respiratory delivery of two or more active agents
JP2014505717A (ja) * 2011-02-17 2014-03-06 シプラ・リミテッド 医薬組成物
WO2012158166A1 (en) * 2011-05-17 2012-11-22 Pearl Therapeutics, Inc. Compositions, methods & systems for respiratory delivery of two or more active agents

Also Published As

Publication number Publication date
CL2015003422A1 (es) 2016-09-02
ZA201509016B (en) 2018-07-25
KR20160013134A (ko) 2016-02-03
WO2014190204A1 (en) 2014-11-27
PE20160155A1 (es) 2016-04-01
HK1221653A1 (zh) 2017-06-09
EP2999460A1 (en) 2016-03-30
CR20150645A (es) 2016-02-10
RU2015154720A (ru) 2017-06-27
AU2014268482A1 (en) 2016-01-07
HK1221654A1 (zh) 2017-06-09
SG11201509543YA (en) 2015-12-30
MX2015016058A (es) 2016-12-20
US20150150787A1 (en) 2015-06-04
JP2016519160A (ja) 2016-06-30
PH12015502593A1 (en) 2016-02-29
DOP2015000284A (es) 2016-04-29
CN105392471A (zh) 2016-03-09
CA2912927A1 (en) 2014-11-27
BR112015028964A2 (pt) 2017-07-25

Similar Documents

Publication Publication Date Title
NI201500163A (es) Composiciones, métodos y sistemas para el suministro por vía respiratoria de tres o más agentes activos.
MX2024013963A (es) Un antagonista de il-4r util para el tratamiento o la prevencion del asma
MX2015009772A (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
UY35663A (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
CR20140508A (es) Moduladores de la ruta del complemento y usos de los mismos
CR20150326A (es) Inhibidores de autotaxina
ECSP14013199A (es) Compuestos para el tratamiento y profilaxis de la enfermedad del virus sincicial respiratorio
PE20151437A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
CR20180232A (es) Macrociclos peptídicos contra acinetobacter baumannii
CR20160518A (es) Compuestos para tratar atrofia muscular espinal
UY34984A (es) Métodos para tratar o prevenir asma administrando un antagonista de il-4r.
MX2018015709A (es) Derivados de azabencimidazol como inhibidores de pi3k beta.
MX392839B (es) Liberacion autorregulada de ingrediente farmaceutico activo.
DOP2014000008A (es) 4-imidazopiridazina-1-il-benzamidas y 4-imidazotriazina-1-il-benzamidas como inhibidores de btk
CU20130094A7 (es) Moduladores de la vía del complemento
CR20140032A (es) Compuestos de tetrahidropirido-piridina y tetrahidropirido-pirimidina y su uso como modulares de receptores de c5a
UY35273A (es) Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con defici encia de smn
CU20160007A7 (es) Derivados de 2((( oxadiazol/triazol/tetrazol/isoxazol) metil) fenil)-1-(heterociclil)-ona como inhibidores activos de autotaxina
PE20151438A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
ECSP14013215A (es) Compuestos novedosos
CR20170003A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
UY35455A (es) Inhibidores tripeptidicos de la epoxicetona proteasa
AR093382A1 (es) Dispositivo de administracion de farmacos para el tratamiento de pacientes con enfermedades respiratorias
CR20130569A (es) Análogos del ácido epoxieicosatrienoicos y métodos de toma y uso del mismo